43 results on '"Saito, Tomohisa"'
Search Results
2. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
3. A Population Pharmacokinetic Analysis of Emicizumab in Patients with Acquired Hemophilia a Enrolled in a Phase III Study (AGEHA)
4. Quantitative Estimation of the In Vivo Equivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data
5. Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic‐Pharmacodynamic Modeling and Simulation
6. Predominant microvessel proliferation in coronary stent restenotic tissue in patients with diabetes: Insights from optical coherence tomography image analysis
7. Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example
8. Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Platelet Decrease Induced by Peg-interferon-alpha 2a
9. A Healthy Volunteer-Derived, Factor VIII-Neutralized, Acquired Hemophilia a-Mimetic Plasma Produces Similar Pharmacodynamic Responses of Emicizumab to Those in Patients with Congenital Hemophilia a with or without Inhibitors
10. Maxacalcitol Pharmacokinetic–Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis
11. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
12. Diastereoselective syntheses and oxygenation of silyl fulleroids
13. Mitigating Bond Deterioration under Cyclic Loading and Water Exposure
14. Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma
15. Population pharmacokinetic–pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor
16. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study
17. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis
18. Maxacalcitol Pharmacokinetic–Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis.
19. Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?
20. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor
21. Prediction of Human Blood-to-Plasma Drug Concentration Ratio
22. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses
23. Rapid Degradation of Concrete Anchorage Performance by Liquid Water
24. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus
25. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study.
26. Reversible mechanochromic luminescence of [[([C.sub.6][F.sub.5]Au).sub.2]([mu]-1, 4-diisocyanobenzene)]
27. Pharmacokinetics and Pharmacodynamics of Tofogliflozin (a Selective SGLT2 Inhibitor) in Healthy Male Subjects
28. Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
29. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
30. Combining ‘Bottom-Up’ and ‘Top-Down’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example
31. Quantitative Estimation of the In VivoEquivalent Factor VIII Activity of NXT007, an Emicizumab-Based, Next-Generation, Activated Factor VIII-Mimetic Bispecific Antibody, from Nonclinical Data
32. Development Overview of Pegasys^|^reg; (Pegylated interferon alpha -2a(40kD))
33. Epstein‐ B arr virus‐associated primary central nervous system cytotoxic T ‐cell lymphoma
34. Abstract 9330: In-stent Restenotic Tissue with a Microchannel in Patients with Diabetes: Insights from Coronary Optical Coherence Tomography Image Analysis
35. Gold(I) Hydride Intermediate in Catalysis: Dehydrogenative Alcohol Silylation Catalyzed by Gold(I) Complex
36. A Simulation Study to Evaluate Limited Sampling Strategies to Estimate Area under the Curve of Drug Concentration versus Time Following Repetitive Oral Dosing: Limited Sampling Model versus Naive Trapezoidal Method
37. Reversible Mechanochromic Luminescence of [(C6F5Au)2(μ-1,4-Diisocyanobenzene)]
38. Typhoon Simulation incorporating Effects of Sea-Surface Temperature
39. Wind Engineers, JAWE
40. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
41. 高度頸動脈狭窄病変を有する患者における、負荷心エコー図検査の有用性:頸動脈ステント留置術者での検討
42. Reversible Mechanochromic Luminescence of [(C6F5Au)2(μ-1 ,4-Diisocyanobenzene)].
43. Clinical Efficacy of Pre-Hospital Electrocardiogram Transmission in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.